AAV-RPGR gene therapy improves retinal sensitivity in 73.8% of XLRP patientsGene therapy shows promise for patients with X-linked retinitis pigmentosa

Journal of translational medicine Published August 15, 2026 Study authors: Chen Kai-Yang, Chan Hoi-Chun, Chan Chi-Ming PubMed ↗ DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider AAV-RPGR gene therapy as a promising but early-stage option for XLRP, with functional gains in a majority of patients.

This meta-analysis pooled data from 12 clinical reports evaluating AAV-mediated RPGR gene augmentation in patients with X-linked retinitis pigmentosa (XLRP). The analysis included 33 participants for retinal sensitivity, 52 for visual function, and 90 for adverse events. The primary outcome was retinal sensitivity improvement, with secondary outcomes including visual function improvement, intraocular inflammation, and intraocular-pressure elevation.

Pooled results showed retinal sensitivity improvement in 73.8% of participants (25/33; 95% CI, 56.0%-86.1%). Visual function improvement was observed in 52.3% (28/52; 95% CI, 38.0%-66.2%). These findings suggest clinically relevant functional signals across multiple outcome domains.

Safety analysis revealed adverse events in 42.6% of participants (42/90; 95% CI, 27.2%-59.5%). The authors noted a structured and monitorable ocular safety profile, though higher vector exposure was associated with greater inflammatory or ocular serious adverse-event frequencies. Serious adverse events and discontinuations were not reported.

The meta-analysis provides a rigorous framework for future development, but it is based on 12 reports rather than a single large clinical trial. Limitations were not reported, and follow-up duration was not specified. Clinicians should interpret these pooled estimates cautiously, given the small sample sizes and lack of comparator data.

Living with X-linked retinitis pigmentosa can mean facing a steady loss of vision. Recent data from 12 clinical reports offer a look at how AAV-RPGR gene therapy might change that experience. The study looked at patients receiving this specific gene treatment to see if it could protect their sight.

Researchers found that about 74% of participants showed improved retinal sensitivity, while over half saw improvements in their overall visual function. While the data comes from a collection of different reports rather than one large trial, these results suggest the therapy provides meaningful functional signals for those with this condition.

Safety is a key part of the conversation. About 43% of participants experienced some form of adverse event, such as eye inflammation or pressure changes. However, experts noted that these issues followed a structured and monitorable safety profile. Higher doses were linked to more frequent inflammatory responses, making careful monitoring essential for patients.

What this means for you:

AAV-RPGR gene therapy shows promising improvements in vision and retinal sensitivity for X-linked retinitis pigmentosa.

Common questions

How effective is this gene therapy for vision?

The data shows that 73.8% of participants experienced an improvement in retinal sensitivity. Additionally, 52.3% of the participants saw improvements in their overall visual function. These results are based on a collection of 12 clinical reports involving several patients.

Is the treatment safe for the eyes?

The therapy has a structured and monitorable safety profile. While about 42.6% of participants experienced some adverse events, such as inflammation or pressure changes, these were tracked closely. Higher levels of the gene vector were linked to more frequent inflammatory responses.

Who is this treatment for?

This specific AAV-RPGR gene therapy is intended for patients diagnosed with X-linked retinitis pigmentosa. It aims to provide functional improvements in both retinal sensitivity and general vision for those living with the condition.

Study Details

Study typeMeta analysis

Sample sizen = 33

EvidenceLevel 1

PublishedAug 2026

PMID42576225

View Original Abstract ↓

BACKGROUND: X-linked retinitis pigmentosa (XLRP) represents a severe inherited retinal dystrophy associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene. Adeno-associated virus (AAV)-mediated RPGR gene augmentation is designed to preserve photoreceptor structure and function. OBJECTIVES: The purpose of this study was to critically appraise and quantitatively synthesize the efficacy and safety evidence for AAV-RPGR gene therapy in X-linked retinitis pigmentosa. METHODS: Scopus, PubMed, the Cochrane Library, ScienceDirect, and Google Scholar were searched from inception through July 11, 2026. Two reviewers independently screened records, two reviewers assessed risk of bias, and extracted data were verified by a second reviewer. Proportions were synthesized using inverse-variance fixed-effect logit models with a 0.5 continuity correction for zero or all-event cells; DerSimonian-Laird random-effects models were used as sensitivity analyses. Cohort linkage, dose-stratified safety, and overlap-adjusted analyses were performed. RESULTS: The search identified 571 records and included 12 clinical reports. Pooled retinal sensitivity improvement was 73.8% (95% confidence interval, 56.0%-86.1%; 25/33 participants), and pooled visual function improvement was 52.3% (95% confidence interval, 38.0%-66.2%; 28/52 participants). The pooled adverse-event proportion was 42.6% (95% confidence interval, 27.2%-59.5%; 42/90 participants), intraocular inflammation was 45.5% (95% confidence interval, 34.6%-56.8%; 36/81 participants), and intraocular-pressure elevation was 34.9% (95% confidence interval, 24.2%-47.4%; 22/63 participants). Product-specific dose analyses showed greater inflammatory or ocular serious adverse-event frequencies at higher vector exposure. CONCLUSION: AAV-RPGR gene therapy demonstrates clinically relevant functional signals across multiple outcome domains with a structured and monitorable ocular safety profile. Cohort-linked synthesis, dose-specific interpretation, standardized outcome definitions, and long-term multinational follow-up provide a rigorous framework for subsequent clinical development.

AAV-RPGR gene therapy improves retinal sensitivity in 73.8% of XLRP patientsGene therapy shows promise for patients with X-linked retinitis pigmentosa

Common questions

Study Details

Systematic review of extensive macular atrophy with pseudodrusen reports visual acuity decline and atrophy progression

Eye disease linked to vision loss and thicker eye layers in study

Clinical research that matters. Delivered to your inbox.

AAV-RPGR gene therapy improves retinal sensitivity in 73.8% of XLRP patientsGene therapy shows promise for patients with X-linked retinitis pigmentosa

Common questions

Study Details

Systematic review of extensive macular atrophy with pseudodrusen reports visual acuity decline and atrophy progression

Eye disease linked to vision loss and thicker eye layers in study

Clinical research that matters. Delivered to your inbox.

Related in Ophthalmology

From Other Specialties